Shop Rx Act of 2019

21st Century Cures Act (P.L. 114-255) implementation and oversight; SUPPORT for Patients and Communities Act (P.L. 115-271) implementation and oversight; Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/HR 4932); Issues related to health data privacy; Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (HR 2740) - issues related to unique patient identifier and patient matching; the Analyzing and Leveraging Existing Rx Transactions Act of 2019 (H.R. 1845); the Protecting Jessica Grubbs Legacy Act (S. 3374); The Mental Health Telemedicine Expansion Act (HR 1301); the Shop Rx Act (HR 3408); The Real-Time Beneficiary Drug Cost Bill (HR 3415); issues related to patient access to data; issues related to pharmacy real-time benefit transactions; issues related to Medicare coverage of telehealth services; issues relating to increased access to treatment for opioid misuse and abuse; issues relating to increased use of technology to combat opioid epidemic; Prescription Drug Pricing Reduction Act (S. 2543); Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act (H.R. 2115); issues related to the COVID-19 pandemic response; Issues around CDC and data infrastructure modernization: H.R. 748, the Coronavirus Aid, Relief and Economic Security (CARES) Act, H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act. Issues related to telemental and telebehavioral health; issues related to remote patient monitoring; the Increasing Rural Health Access During the COVID-19 Public Health Emergency Act of 2020 (H.R. 7190/S. 3951); issues related to ERISA and telehealth; issues related to broadband and infrastructure development; the Protecting Access to Post-Covid-19 Telehealth Act; issues related to modernization of HCAHPS.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues relating to the use of real-time benefit tools in healthcare including S. 2543, the Prescription Drug Pricing Reduction Act; HR 3408, the Shop Rx Act; HR 3415 the Real-Time Beneficiary Drug Cost Act; HR 2115, the Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Electronic Prior Authorization; HR 3408, the Shop Rx Act, HR 3415, the Real-Time Beneficiary Drug Cost bill, HR 2296, HR 2115, the Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act; the METRIC Act and S 2543, the Prescription Drug Pricing Reduction Act, all relating to providing for the use of Real-Time Benefit Tools in healthcare; Implementation of P.L. 115-271, the SUPPORT for Patients and Communities Act providing for prevention, recovery and treatment of opioid use disorder; HR 3924/S 1861, the Streamlining Part D Appeals Process Act relating to coverage determinations and the Medicare appeals process.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; H.R. 1034 / S. 640, Phair Pricing Act of 2019; H.R. 1035, Prescription Drug Price Transparency Act, S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs; H.R.448 / S. 99, Medicare Drug Price Negotiation Act; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019; H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019; H.R. 366, Insulin Access for All Act of 2019; S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; S. 205 / H.R. 937, Right Rebate Act of 2019; H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019; H.R. 1781 / S. 801, the Payment Commission Data Act of 2019; H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers; Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"; Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P"; Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P; H.R. 1323, Rural Hospital Frontier Fairness Act; S. 551, REFUND Act of 2019; S. 691, Medicare Extra Rx HELP Act of 2019; S. 773, Telehealth Innovation and Improvement Act of 2019; S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019; H.R. 1384 / S. 1129, Medicare for All Act of 2019; H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019; H.R. 3408, Shop Rx Act of 2019; S. 1384, Prescription Drug Rebate Reform Act of 2019; H.R. 2113, Prescription Drug STAR Act; H.R. 2115, Public Disclosure of Drug Discounts Act S. 2447, the Phair Relief Act; S. 2771, the Protecting Home Oxygen and Medical Equipment Act of 2019; S. 1861 / H.R. 3924, the Streamlining Part D Appeals Process Act; H.R. 4946, the Ensuring Seniors Access to Local Pharmacies Act of 2019; H.R. 5281, the Drug Price Transparency in Medicaid Act of 2019; H.R. 5442, the Lowest Price for Patients Act; Report language for H.R.1865, the Further Consolidated Appropriations Act; Pharmacist Provider Status draft legislation

H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; H.R. 1034 / S. 640, Phair Pricing Act of 2019; H.R. 1035, Prescription Drug Price Transparency Act, S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs; H.R.448 / S. 99, Medicare Drug Price Negotiation Act; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019; H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019; H.R. 366, Insulin Access for All Act of 2019; S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; S. 205 / H.R. 937, Right Rebate Act of 2019; H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019; H.R. 1781 / S. 801, the Payment Commission Data Act of 2019; H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers; Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"; Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P"; Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P; H.R. 1323, Rural Hospital Frontier Fairness Act; S. 551, REFUND Act of 2019; S. 691, Medicare Extra Rx HELP Act of 2019; S. 773, Telehealth Innovation and Improvement Act of 2019; S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019; H.R. 1384 / S. 1129, Medicare for All Act of 2019; H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019; H.R. 3408, Shop Rx Act of 2019; S. 1384, Prescription Drug Rebate Reform Act of 2019; H.R. 2113, Prescription Drug STAR Act; H.R. 2115, Public Disclosure of Drug Discounts Act S. 2447, the Phair Relief Act; S. 2771, the Protecting Home Oxygen and Medical Equipment Act of 2019; S. 1861 / H.R. 3924, the Streamlining Part D Appeals Process Act; H.R. 4946, the Ensuring Seniors Access to Local Pharmacies Act of 2019; H.R. 5281, the Drug Price Transparency in Medicaid Act of 2019; H.R. 5442, the Lowest Price for Patients Act; Report language for H.R.1865, the Further Consolidated Appropriations Act; Pharmacist Provider Status draft legislation

21st Century Cures Act (P.L. 114-255) implementation and oversight; SUPPORT for Patients and Communities Act (P.L. 115-271) implementation and oversight; Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/HR 4932); Issues related to health data privacy; Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (HR 2740) - issues related to unique patient identifier and patient matching; the Analyzing and Leveraging Existing Rx Transactions Act of 2019 (H.R. 1845); The Overdose Prevention and Patient Safety Act (HR 2062); the Protecting Jessica Grubbs Legacy Act (S. 1012 and S. 3374); The Mental Health Telemedicine Expansion Act (HR 1301); the Shop Rx Act (HR 3408); The Real-Time Beneficiary Drug Cost Bill (HR 3415); issues related to patient access to data; issues related to pharmacy real-time benefit transactions; issues related to Medicare coverage of telehealth services; issues relating to increased access to treatment for opioid misuse and abuse; issues relating to increased use of technology to combat opioid epidemic; Prescription Drug Pricing Reduction Act (S. 2543); Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act (H.R. 2115); issues related to the COVID-19 pandemic response; Issues around CDC and data infrastructure modernization: H.R. 748, the Coronavirus Aid, Relief and Economic Security (CARES) Act, H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act. Issues related to telemental and telebehavioral health; issues related to remote patient monitoring; the Increasing Rural Health Access During the COVID-19 Public Health Emergency Act of 2020 (H.R. 7190/S. 3951); issues related to ERISA and telehealth; issues related to broadband and infrastructure development; the Protecting Access to Post-Covid-19 Telehealth Act.

Issues relating to the use of real-time benefit tools in healthcare including S. 2543, the Prescription Drug Pricing Reduction Act; HR 3408, the Shop Rx Act; HR 3415 the Real-Time Beneficiary Drug Cost Act; HR 2115, the Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Electronic Prior Authorization; HR 3408, the Shop Rx Act, HR 3415, the Real-Time Beneficiary Drug Cost bill, HR 2296, HR 2115, the Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act; the METRIC Act and S 2543, the Prescription Drug Pricing Reduction Act, all relating to providing for the use of Real-Time Benefit Tools in healthcare; Implementation of P.L. 115-271, the SUPPORT for Patients and Communities Act providing for prevention, recovery and treatment of opioid use disorder; HR 3924/S 1861, the Streamlining Part D Appeals Process Act relating to coverage determinations and the Medicare appeals process.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to medication adherence, drug price transparency, and prescription drug abuse. H.R. 748, The Coronavirus Aid, Relief, and Economic Security Act H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 2113, The Prescription Drug Sunshine, Transparency, Accountability and Reporting Act of 2019 H.R. 2115, The Public Disclosure of Drug Pricing Act of 2019 H.R. 3408, The Shop Rx Act of 2019 S. 1895, The Lower Health Care Costs Act of 2019 S. 2543, The Prescription Drug Pricing Reduction Act of 2019

Client expense: $3,460,000 · Firm income: Not reported

Issues related to the Medicare Part D, Medicare Advantage, Medicaid, and ESRD programs. Issues related to CMS Medicare Advantage Advance Rate Notice and Draft Call Letter for 2020. H.R. 3, The Lower Drug Costs Now Act of 2019 H.R. 748, The Coronavirus Aid, Relief, and Economic Security Act H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 3408, The Shop Rx Act of 2019 S. 476, The Creating Transparency to Have Drug Rebates Unlocked Act of 2019 S. 1895, The Lower Health Care Costs Act of 2019 S.2543, The Prescription Drug Pricing Reduction Act of 2019 S.2751, The Patient Access to ESRD New Innovative Devices Act of 2019 S. 3013, The Encouraging Innovative Benefit Design to Lower Costs for Seniors Act of 2019 S. 3129, The Lower Costs, More Cures Act of 2019

Client expense: $3,460,000 · Firm income: Not reported

H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; H.R. 1034 / S. 640, Phair Pricing Act of 2019; H.R. 1035, Prescription Drug Price Transparency Act, S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs; H.R.448 / S. 99, Medicare Drug Price Negotiation Act; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019; H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019; H.R. 366, Insulin Access for All Act of 2019; S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; S. 205 / H.R. 937, Right Rebate Act of 2019; H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019; H.R. 1781 / S. 801, the Payment Commission Data Act of 2019; H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers; Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"; Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P"; Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P; H.R. 1323, Rural Hospital Frontier Fairness Act; S. 551, REFUND Act of 2019; S. 691, Medicare Extra Rx HELP Act of 2019; S. 773, Telehealth Innovation and Improvement Act of 2019; S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019; H.R. 1384 / S. 1129, Medicare for All Act of 2019; H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019; H.R. 3408, Shop Rx Act of 2019; S. 1384, Prescription Drug Rebate Reform Act of 2019; H.R. 2113, Prescription Drug STAR Act; H.R. 2115, Public Disclosure of Drug Discounts Act S. 2447, the Phair Relief Act; S. 2771, the Protecting Home Oxygen and Medical Equipment Act of 2019; S. 1861 / H.R. 3924, the Streamlining Part D Appeals Process Act; H.R. 4946, the Ensuring Seniors Access to Local Pharmacies Act of 2019; H.R. 5281, the Drug Price Transparency in Medicaid Act of 2019; H.R. 5442, the Lowest Price for Patients Act; Report language for H.R.1865, the Further Consolidated Appropriations Act; Pharmacist Provider Status draft legislation

21st Century Cures Act (P.L. 114-255) implementation and oversight; SUPPORT for Patients and Communities Act (P.L. 115-271) implementation and oversight; Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/HR 4932); Issues related to health data privacy; Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (HR 2740) - issues related to unique patient identifier and patient matching; the Analyzing and Leveraging Existing Rx Transactions Act of 2019 (H.R. 1845); The Overdose Prevention and Patient Safety Act (HR 2062); the Protecting Jessica Grubbs Legacy Act (S. 1012 and S. 3374); The Mental Health Telemedicine Expansion Act (HR 1301); the Shop Rx Act (HR 3408); The Real-Time Beneficiary Drug Cost Bill (HR 3415); issues related to patient access to data; issues related to pharmacy real-time benefit transactions; issues related to Medicare coverage of telehealth services; issues relating to increased access to treatment for opioid misuse and abuse; issues relating to increased use of technology to combat opioid epidemic; Prescription Drug Pricing Reduction Act (S. 2543); Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act (H.R. 2115); issues related to the COVID-19 pandemic response

Client expense: Not reported · Firm income: $20,000

Electronic Prior Authorization; HR 3408, the Shop Rx Act, HR 3415, the Real-Time Beneficiary Drug Cost bill, HR 2296, HR 2115, the Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act; the METRIC Act and S 2543, the Prescription Drug Pricing Reduction Act, all relating to providing for the use of Real-Time Benefit Tools in healthcare; Implementation of P.L. 115-271, the SUPPORT for Patients and Communities Act providing for prevention, recovery and treatment of opioid use disorder; HR 3924/S 1861, the Streamlining Part D Appeals Process Act relating to coverage determinations and the Medicare appeals process.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to the Medicare Part D, Medicare Advantage, Medicaid, and ESRD programs. Issues related to CMS Medicare Advantage Advance Rate Notice and Draft Call Letter for 2020. S. 476, The Creating Transparency to Have Drug Rebates Unlocked Act of 2019 H.R. 3, The Lower Drug Costs Now Act of 2019 H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 1034/S. 640, The Phair Pricing Act of 2019 H.R. 1035, The Prescription Drug Price Transparency Act of 2019 H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 2296, The Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R. 3408, The Shop Rx Act of 2019 S.2543, The Prescription Drug Pricing Reduction Act of 2019 S.2751, The Patient Access to ESRD New Innovate Device Act of 2019

Client expense: $2,262,000 · Firm income: Not reported

Issues related to medication adherence, drug price transparency, and prescription drug abuse. H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 1034/S. 640, The Phair Pricing Act of 2019 H.R. 1035, The Prescription Drug Price Transparency Act of 2019 H.R. 1865, Further Consolidated Appropriations Act, 2020 H.R. 2113, The Prescription Drug Sunshine, Transparency, Accountability and Reporting Act of 2019 H.R. 2115, The Public Disclosure of Drug Pricing Act of 2019 H.R. 2296, The Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R. 3408, The Shop Rx Act of 2019 S. 1895, The Lower Health Care Costs Act of 2019 S. 2543, The Prescription Drug Pricing Reduction Act of 2019

Client expense: $2,262,000 · Firm income: Not reported

H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; H.R. 1034 / S. 640, Phair Pricing Act of 2019; H.R. 1035, Prescription Drug Price Transparency Act, S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs; H.R.448 / S. 99, Medicare Drug Price Negotiation Act; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019; H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019; H.R. 366, Insulin Access for All Act of 2019; S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; S. 205 / H.R. 937, Right Rebate Act of 2019; H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019; H.R. 1781 / S. 801, the Payment Commission Data Act of 2019; H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers; Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"; Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P"; Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P; H.R. 1323, Rural Hospital Frontier Fairness Act; S. 551, REFUND Act of 2019; S. 691, Medicare Extra Rx HELP Act of 2019; S. 773, Telehealth Innovation and Improvement Act of 2019; S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019; H.R. 1384 / S. 1129, Medicare for All Act of 2019; H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019; H.R. 3408, Shop Rx Act of 2019; S. 1384, Prescription Drug Rebate Reform Act of 2019; H.R. 2113, Prescription Drug STAR Act; H.R. 2115, Public Disclosure of Drug Discounts Act S. 2447, the Phair Relief Act; S. 2771, the Protecting Home Oxygen and Medical Equipment Act of 2019; S. 1861 / H.R. 3924, the Streamlining Part D Appeals Process Act; H.R. 4946, the Ensuring Seniors Access to Local Pharmacies Act of 2019; H.R. 5281, the Drug Price Transparency in Medicaid Act of 2019; H.R. 5442, the Lowest Price for Patients Act; Report language for H.R.1865, the Further Consolidated Appropriations Act

21st Century Cures Act (P.L. 114-255) implementation and oversight; SUPPORT for Patients and Communities Act (P.L. 115-271) implementation and oversight; Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/HR 4932); Issues related to health data privacy; Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (HR 2740) - issues related to unique patient identifier and patient matching; the Analyzing and Leveraging Existing Rx Transactions Act of 2019 (H.R. 1845); The Overdose Prevention and Patient Safety Act (HR 2062); the Protecting Jessica Grubbs Legacy Act (S. 1012); The Mental Health Telemedicine Expansion Act (HR 1301); the Shop Rx Act (HR 3408); The Real-Time Beneficiary Drug Cost Bill (HR 3415); issues related to patient access to data; issues related to pharmacy real-time benefit transactions; issues related to Medicare coverage of telehealth services; issues relating to increased access to treatment for opioid misuse and abuse; issues relating to increased use of technology to combat opioid epidemic; Prescription Drug Pricing Reduction Act (S. 2543); Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act (H.R. 2115)

Client expense: Not reported · Firm income: $20,000

21st Century Cures Act (P.L. 114-255) implementation and oversight; SUPPORT for Patients and Communities Act (P.L. 115-271) implementation and oversight; the Reducing Unnecessary Senior Hospitalization Act (HR 6502, 115th); the Analyzing and Leveraging Existing Rx Transactions Act of 2019 (H.R. 1845); The Overdose Prevention and Patient Safety Act (HR 2062); the Protecting Jessica Grubbs Legacy Act (S. 1012); The Mental Health Telemedicine Expansion Act (HR 1301); the Shop Rx Act (HR 3408); The Real-Time Beneficiary Drug Cost Bill (HR 3415); issues related to patient access to data; issues related to pharmacy real-time benefit transactions; issues related to Medicare coverage of telehealth services; issues relating to increased access to treatment for opioid misuse and abuse; issues relating to increased use of technology to combat opioid epidemic; Prescription Drug Pricing Reduction Act (S. 2543); Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act (H.R. 2115)

Client expense: Not reported · Firm income: $20,000

Electronic Prior Authorization; HR 3408, the Shop Rx Act, HR 3415, the Real-Time Beneficiary Drug Cost bill, HR 2296, HR 2115, the Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act; the METRIC Act and S 2543, the Prescription Drug Pricing Reduction Act, all relating to providing for the use of Real-Time Benefit Tools in healthcare; Implementation of P.L. 115-271, the SUPPORT for Patients and Communities Act providing for prevention, recovery and treatment of opioid use disorder; HR 3924/S 1861, the Streamlining Part D Appeals Process Act relating to coverage determinations and the Medicare appeals process.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to medication adherence, drug price transparency, and prescription drug abuse. H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 1034/S. 640, The Phair Pricing Act of 2019 H.R. 1035, The Prescription Drug Price Transparency Act of 2019 H.R. 2113, The Prescription Drug Sunshine, Transparency, Accountability and Reporting Act of 2019 H.R. 2115, The Public Disclosure of Drug Pricing Act of 2019 H.R. 2296, The Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R. 3408, the Shop Rx Act of 2019 S. 1895, The Lower Health Care Costs Act of 2019 The Prescription Drug Pricing Reduction Act of 2019 (no bill number assigned)

Client expense: $2,625,000 · Firm income: Not reported

Issues related to the Medicare Part D, Medicare Advantage, Medicaid, and ESRD programs. Issues related to HHS Proposed Rule Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Medicare Advantage Advance Rate Notice and Draft Call Letter for 2020. S. 476, The Creating Transparency to Have Drug Rebates Unlocked Act of 2019 H.R. 3, The Lower Drug Costs Now Act of 2019 H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 1034/S. 640, The Phair Pricing Act of 2019 H.R. 1035, The Prescription Drug Price Transparency Act of 2019 H.R. 2296, The Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R. 3408, the Shop Rx Act of 2019 The Prescription Drug Pricing Reduction Act of 2019 (no bill number assigned)

Client expense: $2,625,000 · Firm income: Not reported

21st Century Cures Act (P.L. 114-255) implementation and oversight; SUPPORT for Patients and Communities Act (P.L. 115-271) implementation and oversight; the Reducing Unnecessary Senior Hospitalization Act (HR 6502, 115th); The Analyzing and Leveraging Existing Rx Transactions Act (HR 1845); The Overdose Prevention and Patient Safety Act (HR 2062); the Protecting Jessica Grubbs Legacy Act (S. 1012); The Mental Health Telemedicine Expansion Act (HR 1301); the Shop Rx Act (HR 3408); The Real-Time Beneficiary Drug Cost Bill (HR 3415); issues related to patient access to data; issues related to pharmacy real-time benefit transactions; issues related to Medicare coverage of telehealth services; issues relating to increased access to treatment for opioid misuse and abuse; issues relating to increased use of technology to combat opioid epidemic.

Client expense: Not reported · Firm income: $20,000

H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; H.R. 1034 / S. 640, Phair Pricing Act of 2019; H.R. 1035, Prescription Drug Price Transparency Act, S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs; H.R.448 / S. 99, Medicare Drug Price Negotiation Act; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019; H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019; H.R. 366, Insulin Access for All Act of 2019; S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; S. 205 / H.R. 937, Right Rebate Act of 2019; H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019; H.R. 1781 / S. 801, the Payment Commission Data Act of 2019; H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers; Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"; Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P"; Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P; H.R. 1323, Rural Hospital Frontier Fairness Act; S. 551, REFUND Act of 2019; S. 691, Medicare Extra Rx HELP Act of 2019; S. 773, Telehealth Innovation and Improvement Act of 2019; S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019; H.R. 1384 / S. 1129, Medicare for All Act of 2019; H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019; H.R. 3408, Shop Rx Act of 2019; S. 1384, Prescription Drug Rebate Reform Act of 2019; H.R. 2113, Prescription Drug STAR Act; H.R. 2115, Public Disclosure of Drug Discounts Act S. 2447, the Phair Relief Act; S. 2771, the Protecting Home Oxygen and Medical Equipment Act of 2019

Electronic Prior Authorization; HR 3408, the Shop Rx Act, HR 3415, the Real-Time Beneficiary Drug Cost bill, HR 2296, the METRIC Act and S 2543, the Prescription Drug Pricing Reduction Act, all relating to providing for the use of Real-Time Benefit Tools in healthcare; Implementation of P.L. 115-271, the SUPPORT for Patients and Communities Act providing for prevention, recovery and treatment of opioid use disorder; HR 3924/S 1861, the Streamlining Part D Appeals Process Act relating to coverage determinations and the Medicare appeals process.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 - Provisions related to reauthorization of the Pandemic and All-Hazards Preparedness Act H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1603: Alan Reinstein Ban Asbestos Now Act of 2019 - Provisions related to use of asbestos in manufacturing H.R. 1730: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing H.R. 2011: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products H.R. 2020: STEER Act - Provisions related to encapsulating & tableting machine registration H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2296: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2584: To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings - Provisions related to CBO scoring of preventive health savings H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: To amend title XI of the Social Security Act to require that direct-to-consumer television advertisements for prescription drugs and biological products include the list price of such drugs and products, and for other purposes - Provisions related to direct-to-consumer prescription drug advertising H.R. 3379: Price Relief, Innovation, and Competition for Essential Drugs or PRICED Act - Provisions related to exclusivity H.R. 3408: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3415: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3443: To clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes - Provisions related to FDA over-the-counter drug approvals S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 419: Protecting Americans from Dangerous Opioids Act - Provisions related to FDA drug approvals S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes S. 474: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 741: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing S. 989: STEER Act - Provisions related to encapsulating & tableting machine registration S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Reauthorization of the Pandemic and All-Hazards Preparedness Act Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)

Issues related to the Medicare Part D, Medicare Advantage, Medicaid, and ESRD programs. Issues related to HHS Proposed Rule Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees. Issues related to CMS Medicare Advantage Advance Rate Notice and Draft Call Letter for 2020 S. 317/H.R. 1226, The Advancing Care for Exceptional Kids Act of 2019 S. 476, The Creating Transparency to Have Drug Rebates Unlocked Act of 2019 H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 1034/S. 640, The Phair Pricing Act of 2019 H.R. 1035, The Prescription Drug Price Transparency Act of 2019 H.R. 2296, The Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R. 3408, the Shop Rx Act of 2019

Client expense: $2,200,000 · Firm income: Not reported

Issues related to medication adherence, drug price transparency, and prescription drug abuse. H.R. 803/S. 988, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2019 H.R. 1034/S. 640, The Phair Pricing Act of 2019 H.R. 1035, The Prescription Drug Price Transparency Act of 2019 H.R. 1614/S. 724, The John S. McCain Opioid Addiction Prevention Act of 2019 H.R. 2113, The Prescription Drug Sunshine, Transparency, Accountability and Reporting Act of 2019 H.R. 2115, The Public Disclosure of Drug Pricing Act of 2019 H.R. 2296, The Fair Accountability and Innovative Research Drug Pricing Act of 2019 H.R. 3408, the Shop Rx Act of 2019 S. 1895, The Lower Health Care Costs Act of 2019

Client expense: $2,200,000 · Firm income: Not reported

H.R. 269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 - Provisions related to reauthorization of the Pandemic and All-Hazards Preparedness Act H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1603: Alan Reinstein Ban Asbestos Now Act of 2019 - Provisions related to use of asbestos in manufacturing H.R. 1730: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing H.R. 1922: Restoring Access to Medicine Act H.R. 2011: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products H.R. 2020: STEER Act - Provisions related to encapsulating & tableting machine registration H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2296: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2584: To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings - Provisions related to CBO scoring of preventive health savings H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: To amend title XI of the Social Security Act to require that direct-to-consumer television advertisements for prescription drugs and biological products include the list price of such drugs and products, and for other purposes - Provisions related to direct-to-consumer prescription drug advertising H.R. 3379: Price Relief, Innovation, and Competition for Essential Drugs or PRICED Act - Provisions related to exclusivity H.R. 3408: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3415: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3443: To clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes - Provisions related to FDA over-the-counter drug approvals S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S.12: Health Savings Account of 2019 S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S.182: Protecting Seniors through Immunization Act S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes S. 474: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 741: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing S. 989: STEER Act - Provisions related to encapsulating & tableting machine registration S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S.1654/H.R. 1973: Vaccine Access Improvement Act S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues Prescription drug take back and secure disposal policy issues Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Reauthorization of the Pandemic and All-Hazards Preparedness Act Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)

H.R. 269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 - Provisions related to reauthorization of the Pandemic and All-Hazards Preparedness Act H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1603: Alan Reinstein Ban Asbestos Now Act of 2019 - Provisions related to use of asbestos in manufacturing H.R. 1730: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing H.R. 2011: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products H.R. 2020: STEER Act - Provisions related to encapsulating & tableting machine registration H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2296: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2584: To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings - Provisions related to CBO scoring of preventive health savings H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: To amend title XI of the Social Security Act to require that direct-to-consumer television advertisements for prescription drugs and biological products include the list price of such drugs and products, and for other purposes - Provisions related to direct-to-consumer prescription drug advertising H.R. 3379: Price Relief, Innovation, and Competition for Essential Drugs or PRICED Act - Provisions related to exclusivity H.R. 3408: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3415: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of such sponsor's electronic prescription program under the Medicare program - Provisions related to drug pricing transparency H.R. 3443: To clarify the regulatory framework with respect to certain nonprescription drugs that are marketed without an approved drug application, and for other purposes - Provisions related to FDA over-the-counter drug approvals S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 419: Protecting Americans from Dangerous Opioids Act - Provisions related to FDA drug approvals S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes S. 474: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 741: Cancer Drug Parity Act of 2019 - Provisions related to prescription drug patient cost-sharing S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing S. 989: STEER Act - Provisions related to encapsulating & tableting machine registration S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Reauthorization of the Pandemic and All-Hazards Preparedness Act Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)

Electronic Prior Authorization; Real-Time Benefit Tools including HR 3408, the Shop Rx Act and HR 3415, the Real-Time Beneficiary Drug Cost Bill; Implementation of P.L. 115-271, the SUPPORT for Patients and Communities Act providing for prevention, recovery and treatment of opioid use disorder

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; H.R. 1034 / S. 640, Phair Pricing Act of 2019; H.R. 1035, Prescription Drug Price Transparency Act, S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs; H.R.448 / S. 99, Medicare Drug Price Negotiation Act; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019; H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019; H.R. 366, Insulin Access for All Act of 2019; S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; S. 205 / H.R. 937, Right Rebate Act of 2019; H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019; H.R. 1781 / S. 801, the Payment Commission Data Act of 2019; H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers; Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"; Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P"; Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P; H.R. 1323, Rural Hospital Frontier Fairness Act; S. 551, REFUND Act of 2019; S. 691, Medicare Extra Rx HELP Act of 2019; S. 773, Telehealth Innovation and Improvement Act of 2019; S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019; H.R. 1384 / S. 1129, Medicare for All Act of 2019; H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019; H.R. 3408, Shop Rx Act of 2019; S. 1384, Prescription Drug Rebate Reform Act of 2019; H.R. 2113, Prescription Drug STAR Act; H.R. 2115, Public Disclosure of Drug Discounts Act

21st Century Cures Act (P.L. 114-255) implementation and oversight; SUPPORT for Patients and Communities Act (P.L. 115-271) implementation and oversight; the Reducing Unnecessary Senior Hospitalization Act (HR 6502, 115th); the Analyzing and Leveraging Existing Rx Transactions Act of 2019 (H.R. 1845); The Analyzing and Leveraging Existing Rx Transactions Act (HR 1845); The Overdose Prevention and Patient Safety Act (HR 2062); the Protecting Jessica Grubbs Legacy Act (S. 1012); The Mental Health Telemedicine Expansion Act (HR 1301); the Shop Rx Act (HR 3408); The Real-Time Beneficiary Drug Cost Bill (HR 3415); issues related to patient access to data; issues related to pharmacy real-time benefit transactions; issues related to Medicare coverage of telehealth services; issues relating to increased access to treatment for opioid misuse and abuse; issues relating to increased use of technology to combat opioid epidemic.

Client expense: Not reported · Firm income: $20,000